Article
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
European journal of cancer (Oxford, England : 1990) - 1 May 2023
Saito Ryota, Sugawara Shunichi, Ko Ryo, Azuma Koichi, Morita Ryo, Maemondo Makoto, Oizumi Satoshi, Takahashi Kazuhisa, Kagamu Hiroshi, Tsubata Yukari, Seike Masahiro, Kikuchi Toshiaki, Okamoto Isamu, Satoshi Morita, Asahina Hajime, Tanaka Kentaro, Sugio Kenji, Kobayashi Kunihiko
Abstract excerpt
BACKGROUND: This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients received osimertinib 80 mg once daily (QD), with either cisplatin 75 mg/m2 (arm A) or carboplatin (area under the curve [AUC] = 5; arm B), plus...
Topics
Join the communities discussing this publication.